RTW Biotech Opportunities (LSE:RTW) Tariff Resilience Score: 0/10 (As of Jul. 06, 2026)


LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
42 GF Score
Price $2.43
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities Tariff Resilience Score?

RTW Biotech Opportunities has the Tariff Resilience Score of 0, which implies that the company might have .

RTW Biotech Opportunities has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes RTW Biotech Opportunities might have .

RTW Biotech Opportunities  (LSE:RTW) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

RTW Biotech Opportunities Tariff Resilience Score Related Terms

LSE:RTW
42GF Score
RTW Biotech Opportunities Ltd LSE:RTW
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
42GF Score

Get the complete analysis for LSE:RTW

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.43
Price